LOGIN  |  REGISTER
Recursion

Phibro Animal Health to Host Webcast and Conference Call on First Quarter Results

October 17, 2023 | Last Trade: US$16.85 0.29 -1.69

TEANECK, N.J. / Oct 17, 2023 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its first quarter financial results on Wednesday, November 8, 2023, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 9, 2023, at 9:00 AM Eastern Time.

Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884.

A replay of the webcast will be available approximately two hours after the conclusion of the live event. To access the webcast recording, visit https://investors.pahc.com.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com.

Our filings with the Securities and Exchange Commission are available online at www.sec.gov, www.pahc.com or on request from the company.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB